ライフサイエンスコーパス: proteasome activity

1 ein-Barr virus of humans inhibits eukaryotic proteasome activity.

2 of FOXO4 but not FOXO1 expression decreased proteasome activity.

3 than mutation-positive patients with normal proteasome activity.

4 f novel anticancer drugs by interfering with proteasome activity.

5 e, proliferation, cell cycle progression and proteasome activity.

6 uction of oxidative stress and inhibition of proteasome activity.

7 ), decreases 5-LOX expression, and increases proteasome activity.

8 irm that PcG protein levels are regulated by proteasome activity.

9 sponse to MG132 treatment and an increase in proteasome activity.

10 f ovariectomized mice did not alter the 26 S proteasome activity.

11 due to up-regulation of Rpn4, which controls proteasome activity.

12 ighly aggregated proteins interfere with 26S proteasome activity.

13 mPI31 is physiologically required for normal proteasome activity.

14 roteasome phosphatase that regulates nuclear proteasome activity.

15 me assembly and selectively enhances nuclear proteasome activity.

16 of subunits Rpt2 and Rpt6 and stimulation of proteasome activity.

17 of alpha B crystallin and increased cardiac proteasome activity.

18 FAP are particularly effective at inhibiting proteasome activity.

19 xtanuclear aggresomes, without affecting 20S proteasome activity.

20 protein 27 (Hsp27) underlies SFN-stimulated proteasome activity.

21 extended Sac3(WT) half-life upon inhibiting proteasome activity.

22 units by caspase-3 as well as the changes in proteasome activity.

23 , caspase-3 cleaves Rpt2 and Rpt6 increasing proteasome activity.

24 des a novel mechanism underlying SFN-induced proteasome activity.

25 yoblasts, caspase-3 cleaves Rpt5 to decrease proteasome activity.

26 , G93A-SOD1 mice showed elevation of OMI and proteasome activity.

27 AMPK inhibited the high-glucose-enhanced 26S proteasome activity.

28 ing, less protein ubiquitination, and higher proteasome activity.

29 ons of GA and inhibitors of GA synthesis and proteasome activity.

30 kinase kinase cleavage), K(+) effluxes, and proteasome activity.

31 e cells, whereas ethanol exposure suppressed proteasome activity.

32 efficient bortezomib-mediated inhibition of proteasome activity.

33 pha-mediated loss of capsid protein requires proteasome activity.

34 light resulted in a 40% to 60% reduction in proteasome activity.

35 ure to blue light alone had little effect on proteasome activity.

36 sed independent of adenosine triphosphate or proteasome activity.

37 of toxic oligomer proteins and a decline in proteasome activity.

38 istration of PSI transiently decreased brain proteasome activity.

39 id activation of Bak and Bax, which required proteasome activity.

40 suppression occurred by attenuating the 26S proteasome activity.

41 mplex III mutant cells also showed decreased proteasome activity.

42 nation of cardiac proteins and increased 26S proteasome activity.

43 8 knock-out mice exhibited elevated cortical proteasome activity.

44 panied by a significant (P<0.05) increase in proteasome activity.

45 t not FOXO1 in HD NPCs dramatically enhanced proteasome activity.

46 nd correlate cytotoxicity with inhibition of proteasome activity.

47 lding, proteasome assembly, and, ultimately, proteasome activity.

48 COI1 co-receptor, a functional Jas motif and proteasome activity.

49 ng-related marker, in the brain and enhanced proteasome activity.

50 ing that the neurotrophin acts by decreasing proteasome activity.

51 proteins and pathways that are sensitive to proteasome activity.

52 on of p38alpha and -gamma, and inhibition of proteasome activity.

53 This was accompanied by an impairment of proteasome activity.

54 for mammalian cells with different levels of proteasome activity.

55 sulting in recovery (i.e., 'bounce-back') of proteasome activity.

56 mained unaltered following the inhibition of proteasome activity.

57 hibitor to determine the background for each proteasome activity.

58 tivity of USP14 and UCHL5 without inhibiting proteasome activity.

59 owder delivery without modification of total proteasome activity.

60 trypsin-like, caspase-like, and trypsin-like proteasome activities.

61 lation of matrix metalloproteinase (MMP) and proteasome activities.

62 between the nucleus and cytosol, 2) decrease proteasome activity, 3) induce endoplasmic reticulum str

63 ntrations of inhibitors that markedly reduce proteasome activity [4].

64 trypsin-like, caspase-like, and trypsin-like proteasome activities; (4) inhibition of nuclear factor

65 reciable increase in K6a gene expression and proteasome activity, a higher level of cytosolic K6a res

66 Renal proteasome activity, a major regulator of NFkappaB-media

67 ization of Hsp60 to the cytosol may modulate proteasome activity according to cell need.

68 complexes persisted when cells had regained proteasome activity after pulse exposure to proteasome i

69 1(-/-) MEFs were impaired in the recovery of proteasome activity after transient treatment with the c

70 vide new evidence that altered expression of proteasome activity after Zif268 induction may be a key

71 mice treated with paraquat showed decreased proteasome activities and increased ubiquitinated protei

72 hus, despite its in vitro effects on various proteasome activities and its structural relationship to

73 asome-specific inhibitors both decreased 26S proteasome activities and prevented C2C12 differentiatio

74 PKG positively regulates proteasome activities and proteasome-mediated degradatio

75 ctivation by sildenafil increased myocardial proteasome activities and significantly decreased myocar

76 dothelial cells to exogenous ONOO- increased proteasome activity and 3-nitrotyrosine in 26S proteasom

77 cytosolic PMP22 coincides with a decrease in proteasome activity and an increase in autophagy-lysosom

78 f IFNgamma, we observed a similar decline in proteasome activity and antigen presentation after ethan

79 , accompanied by a corresponding increase in proteasome activity and cleavage of Rpt2 and Rpt6.

80 NPCs, HD-iPSC-derived neurons showed reduced proteasome activity and diminished FOXO4 expression comp

81 n vivo assays we find that CaMKII stimulates proteasome activity and directly phosphorylates Rpt6, a

82 bortezomib and inhibitor of STAT3 abrogated proteasome activity and enhanced cellular apoptosis.

83 Proteasome activity and expression increase as the infec

84 11 on steady-state levels of ubiquitylation, proteasome activity and expression of Atrogin-1 and MuRF

85 These results reveal a novel link between proteasome activity and expression of ERalpha in breast

86 or cells (NPCs) demonstrated lower levels of proteasome activity and FOXO expressions than their WT c

87 training experience and measured changes in proteasome activity and GluR2 expression in the amygdala

88 table fear associations prevented changes in proteasome activity and glutamate receptor expression in

89 HD iPSCs exhibited elevated proteasome activity and higher levels of FOXO1 and FOXO4

90 gets of NPI-0052 and HDACi are inhibition of proteasome activity and histone acetylation, we initiall

91 own-regulation of PSMA4 expression decreased proteasome activity and induced apoptosis.

92 LPS-induced AKI and the suppression of both proteasome activity and inflammation by nicotinic agonis

93 1 destruction during mitotic arrest requires proteasome activity and is dependent on Cdc20/Fizzy, whi

94 r mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes.

95 A ATPase (RPT2a) causes a weak defect in 26S proteasome activity and leads to an enlargement of leave

96 Proteasome activity and levels of both the constitutive

97 There was no effect of GW610742 on 20S proteasome activity and mRNA expression, or the muscle D

98 n Atrogin-1 and MuRF-1 expression, ubiquitin-proteasome activity and myofiber size modulated by PMI50

99 hich specifically inhibits chymotrypsin-like proteasome activity and no other proteases.

100 activated caspase-1 by a mechanism involving proteasome activity and potassium efflux.

101 rses the inhibitory effects of R239C GFAP on proteasome activity and promotes degradation of the muta

102 scribed the activity-dependent regulation of proteasome activity and recruitment of proteasomes into

103 ate may be an effective strategy to increase proteasome activity and reduce levels of toxic proteins

104 ainst oxidative stress and the inhibition of proteasome activity and resulted in upregulation in expr

105 Our results show that PMI5011 inhibits proteasome activity and steady-state ubiquitylation leve

106 Elevated proteasome activity and subunit expression are found in

107 derstand the pathogenesis of HD, we analyzed proteasome activity and the expression of FOXO transcrip

108 ddition, high glucose increased both the 26S proteasome activity and the ubiquitination of GTPCH.

109 ortezomib-adapted subclones showed increased proteasome activity and tolerated lower proteasome capac

110 by its ability to generate oxidants, alters proteasome activity and whether these alterations are fu

111 ons are protected from caspase activation by proteasome activity and X-linked inhibitor of apoptosis

112 lcade) in its chemical structure, effects on proteasome activities, and mechanisms of action.

113 proteasome subunits LMP7 and LMP2, decreased proteasome activity, and enhanced proteasome inhibitor s

114 lator SKN-1/Nrf increases stress resistance, proteasome activity, and longevity.

115 buffer optimized for cell permeabilization, proteasome activity, and luciferase activity.

116 without affecting overall ubiquitination or proteasome activity, and resulted in a progressive dilat

117 ath via triggering of the ESR, inhibition of proteasome activity, and subsequent accumulation of misf

118 y, exercise attenuated changes in carbonyls, proteasome activity, and synapsin I following FPI, which

119 itinating enzyme Usp14/Ubp6, which regulates proteasome activity, and the ubiquitin ligase, Ube3c/Hul

120 These data suggest that FOXOs modulate proteasome activity, and thus represents a potentially v

121 These cells exhibited enhanced proteasome activity, and transcriptional profiling revea

122 ite its importance the mechanisms regulating proteasome activity are only incompletely understood.

123 of Parkin-expressing cells, and both p97 and proteasome activity are required for Parkin-mediated mit

124 le, yet ligands truly selective for a single proteasome activity are scarce.

125 lzomib we noted a slower rate of recovery of proteasome activity as compared to bortezomib in both pa

126 tion therapies that enhance PP2A and inhibit proteasome activity as novel therapeutic strategies for

127 As such, significantly different proteasome activities, as measured in nmol AMC released/

128 NEL assays, C9 immunohistochemistry, and 20S proteasome activity assays were also performed.

129 ard tumor vs normal cells, inhibition of 26S proteasome activity associated with endoplasmic reticulu

130 These findings suggest that the type of proteasome activity being measured and sample type are i

131 determined that pharmacologic inhibition of proteasome activity blocks proplatelet formation in huma

132 cells, ethanol metabolism decreased not only proteasome activity, but also hydrolysis of the C-extend

133 appeared to be mediated by the inhibition of proteasome activity, but not by ATP depletion or product

134 We also found that inhibition of the proteasome activity, but not the lysosome or the calpain

135 neration HIV protease inhibitors (PIs) alter proteasome activity, but the effect of first- or second-

136 In addition, inhibition of proteasome activity by bortezomib, a drug approved for h

137 Furthermore, inhibition of proteasome activity by curcumin in human colon cancer HC

138 selective proteolysis, and the regulation of proteasome activity by interacting proteins and subunit

139 th long lifespan in invertebrates, regulates proteasome activity by modulating the expression of PSMD

140 this structural role, CaMKIIalpha stimulates proteasome activity by phosphorylating proteasome subuni

141 Taken together, proteasome activity can not only be manipulated through

142 rkin overexpression rescued the reduction of proteasome activity caused by mutant Twinkle in PC12 cel

143 Blocking mitochondrial import but not proteasome activity causes a marked delay in the degrada

144 ibition of inflammatory cytokine production, proteasome activity, cell proliferation and survival, an

145 habditis elegans results in elevated somatic proteasome activity, clearance of damaged proteins and i

146 mRNA, increased activity of PDC and reduced proteasome activity compared with simvastatin.

147 Moreover, chemical or genetic disruption of proteasome activity compromises LFY-dependent AP3 activa

148 cell characteristics, whereas enhancement of proteasome activity conferred attributes of memory lymph

149 nation, and its loading impairs the cellular proteasome activity, consistent with competitive inhibit

150 ata indicate that down-regulation of MMP and proteasome activities constitutes a novel mechanism of P

151 d FPI animals and changed in proportion with proteasome activity/content.

152 endent manner, suggesting that alteration in proteasome activity contributes to the loss of HPK1 prot

153 Ethanol-elicited reduction in proteasome activity contributes to the suppression of SI

154 ys in the presence of MG132, an inhibitor of proteasome activity, demonstrated that the degradation o

155 ory response is mediated by CaMKII, involves proteasome activity, depends on the second intracellular

156 ogether, our results identify enhanced renal proteasome activity during LPS-induced AKI and the suppr

157 lex control over the proteasome, suppressing proteasome activity even when inactive in deubiquitinati

158 We measured the proteasome activity, expression of proteasome subunits,

159 Rac1 to relocalize Net1A, and inhibition of proteasome activity extends the duration and magnitude o

160 active oxygen species, or ubiquitin-mediated proteasome activity fail to suppress this degradation.

161 Inhibition of GA production and proteasome activity feminized male flowers.

162 ion in cultured cardiomyocytes by inhibiting proteasome activity, finding that aggregation of polyubi

163 IkappaB, resulting from concurrently reduced proteasome activity followed by stability of IkappaB.

164 ges correlated with a more rapid recovery of proteasome activity following brief exposure to bortezom

165 rotein also supported the requirement of the proteasome activity for CPT-induced DSBs.

166 It is conceivable that stimulating proteasome activity for rapid removal of misfolded and o

167 Due to the reduction of proteasome activity, formation of cytoplasmic inclusions

168 pha2(-/-) mice, which exhibited elevated 26S proteasome activity, had reduced levels of GTPCH I and B

169 ut (LDLr(-/-)) strain markedly increased 26S proteasome activity, IkappaB degradation, NF-kappaB tran

170 oxidase-mediated superoxide production, 26S proteasome activity, IkappaBalpha degradation, and nucle

171 oxidase-mediated superoxide production, 26S proteasome activity, IkappaBalpha degradation, and nucle

172 Inhibition of proteasome activity, IL-6 activity or either the JAK/STA

173 ferous vegetables, has been shown to enhance proteasome activities in mammalian cells and to reduce t

174 ition of tumor growth and CT-L, C-L, and T-L proteasome activities in tumor cells.

175 a previously unknown mechanism that perturbs proteasome activity in "old-age" female and male Drosoph

176 mate interplay between dopamine receptor and proteasome activity in a nondegenerative context.

177 d SAR In addition, we show that Pst inhibits proteasome activity in a type III secretion-dependent ma

178 ependent inhibition of the chymotrypsin-like proteasome activity in all tissues examined with the exc

179 , we show that ADP-ribosylation promotes 26S proteasome activity in both Drosophila and human cells.

180 of mice caused significant inhibition of the proteasome activity in both Nurr1 knock out heterozygous

181 proteomic analyses revealed that modulating proteasome activity in CD8+ T cells affected cellular me

182 Pharmacologic reduction of proteasome activity in CD8+ T cells early during differe

183 In addition, bortezomib reduced proteasome activity in congenital muscular dystrophy typ

184 Proteasome activity in core-positive 191-20 cells was 20

185 sulfide partially reversed the elevation of proteasome activity in core-positive cells, whereas etha

186 However, proteasome activity in corticosterone-treated DCs or spl

187 Accordingly, BDNF downregulated the proteasome activity in cultured hippocampal neurons and

188 Inhibition of prostate tumor cellular proteasome activity in cultures and in vivo by WA result

189 Proteasome activity in HCM and failing human hearts is i

190 The decrease in proteasome activity in LP was not due to the surge of es

191 ytopenic by tamoxifen-induced suppression of proteasome activity in megakaryocytes and platelets (Psm

192 We find that caspase-3 increases proteasome activity in myotubes but not in myoblasts.

193 Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten k

194 However, NAC did not affect the loss of proteasome activity in response to MG132, demonstrating

195 pecifically degrade RPT6, leading to reduced proteasome activity in the cytoplasm as well as in the n

196 iment in which testing was conducted on WD1, proteasome activity in the NAc was greater after retriev

197 hree different plates but did not affect the proteasome activity in the nonbinding surface microplate

198 uring late-stage pathology, had increases in proteasome activity in the striatum.

199 tulinic acid activated the chymotrypsin-like proteasome activity in three different plates but did no

200 osphorylates the 26S proteasome and inhibits proteasome activity in vitro.

201 vels suppresses defects caused by diminished proteasome activity in vivo.

202 AKT activity increased both FOXO4 level and proteasome activity, indicating a potential role of AKT

203 criptional enrichment of genes that regulate proteasome activity, indicating new therapeutic targets.

204 sed turnover of Fbw7 is dependent on CRL and proteasome activity, indicating that Glmn modulates the

205 ination and can be blocked by suppression of proteasome activity, indicating the involvement of prote

206 erevisiae, chemical or genetic inhibition of proteasome activity induces new proteasome synthesis pro

207 occurred in the presence and absence of the proteasome activity inhibitor MG132 in infected cells.

208 The most common method to measure proteasome activity involves measuring the release of fl

209 Whether proteasome activity is also elevated in response to cata

210 ken together, these results demonstrate that proteasome activity is an important regulator of CD8+ T

211 The impaired ubiquitin-proteasome activity is believed to be one of the leading

212 Previous studies have demonstrated that 26S proteasome activity is diminished in human end-stage hea

213 Measurement of proteasome activity is fast becoming a commonly used ass

214 Proteasome activity is frequently enhanced in cancer to

215 We have recently demonstrated that proteasome activity is increased in laminin alpha2 chain

216 diabetes, skeletal muscle ubiquitylation and proteasome activity is inhibited and Atrogin-1 and MuRF-

217 This ensures that proteasome activity is matched to demand.

218 tors of the proteasome, we show that ongoing proteasome activity is necessary for facilitating the va

219 x and hypothalamus at comparable levels, and proteasome activity is normal in these brain regions of

220 Proteasome activity is regulated by sequestration of its

221 devastating neurodegenerative disorder, how proteasome activity is regulated in HD affected stem cel

222 broad range of cellular activities, yet how proteasome activity is regulated remains poorly understo

223 with a PA28gamma retaining fully functional proteasome activity is required for p30's ability to rep

224 ol different steps in Gcn4 function and that proteasome activity is required for the ability of Gcn4

225 Proteasome activity is required to restrict tudor domain

226 Here, we show that proteasome activity is strongly induced during basal def

227 alpha-synuclein aggregation and the impaired proteasome activity is yet unclear.

228 hoot development, the maintenance of optimal proteasome activity levels is important for balancing ce

229 Impaired proteasome activity may also enhance accumulation of oth

230 te and raise the possibility that increasing proteasome activity may be a useful therapeutic strategy

231 m in schizophrenia, and suggest that altered proteasome activity may be associated with the pathophys

232 In vitro and cell culture-based proteasome activity measurements confirmed that TIR-199

233 phology, gene and miRNA expression analyses, proteasome activity, motor activity, and survival.

234 Notably, elevated nuclear proteasome activity occurred in cells expressing the nuc

235 Regulation of proteasome activity occurs, in part, through a gating me

236 e BDA assay measures the intrinsic ubiquitin/proteasome activity of CLL cells and dynamic changes in

237 Modulation of either proteasome activity or autophagic-lysosomal potential ex

238 a manner that was both rapamycin-sensitive (proteasome activity; phosphorylation of S6K1 and rpS6) a

239 , knocking down murf1 activity or inhibiting proteasome activity preserved myofibril integrity, revea

240 e is paradoxically associated with increased proteasome activity, probably as a cellular compensatory

241 ons by CRL5(SOCS6) and concurrent cullin and proteasome activity provide a negative feedback loop, en

242 that effects of cocaine memory retrieval on proteasome activity, relative to saline memory retrieval

243 ycin b and MG132 to block nuclear export and proteasome activity, respectively.

244 o exhibited low and high rates of endogenous proteasome activity, respectively.

245 cle AAA-ATPase6 (RPT6) in planta to suppress proteasome activity, resulting in the inhibition of sali

246 from Pst for their ability to interfere with proteasome activity revealed HopM1, HopAO1, HopA1, and H

247 ses including cancer, and drugs that inhibit proteasome activity show promise as a form of cancer tre

248 n level observed requires ubiquitination and proteasome activity, strongly suggesting an active degra

249 ichment of genes regulating inflammation and proteasome activities, suggesting a combination of tyros

250 in total protein lysates along with reduced proteasome activity, suggesting diminished protein damag

251 rophages occurred independently of Nalp3 and proteasome activity, suggesting that a previously unchar

252 be rescued by pharmacological inhibition of proteasome activity, suggesting that inappropriate prote

253 Infection with wild-type PtoDC3000 causes proteasome activities that range from strongly induced b

254 an embryonic stem cells (hESCs) exhibit high proteasome activity that is correlated with increased le

255 ination; when combined with the reduction in proteasome activity that is known for COPD, this resista

256 Enhancement of proteasome activity through inhibition of USP14 may offe

257 se data demonstrate that increasing cellular proteasome activity through the direct delivery of purif

258 and HBX functions through the inhibition of proteasome activities to enhance HBV replication in vivo

259 This mechanism enables proteasome activity to adapt to the supply of substrates

260 cells did not correlate with differences in proteasome activity, total RNA content, mRNA content, or

261 d found that most belong to three processes: proteasome activity, vesicle traffic and intracellular s

262 gical phenotypes, systemic inhibition of the proteasome activity via MG132 in postnatal mice could ex

263 Moreover, specific inhibition of 26S proteasome activity via siRNA-mediated knockdown of the

264 Proteasome activity was also determined before and after

265 Elevation of immunoproteasome and proteasome activity was also observed in the livers of l

266 Following IPC, proteasome activity was decreased 25% (P<0.05) in isolat

267 The role of Hsp27 in regulating proteasome activity was further confirmed in isogenic RE

268 Despite these proteolytic defects, overall proteasome activity was increased in sts1-2.

269 the ICP0 RING finger and did not occur when proteasome activity was inhibited.

270 Chymotrypsin-like proteasome activity was measured fluorometrically.

271 Proteasome activity was measured in isolated rat and hum

272 Proteasome activity was monitored using fluorogenic pept

273 PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the

274 A significant increase in 20S proteasome activity was observed with unloading, in para

275 dependent proteasome substrate we found that proteasome activity was reduced.

276 to the effects on posttetanic potentiation, proteasome activity was required for BDNF-mediated LTP.

277 tely 50% during LPS-induced AKI and elevated proteasome activity was significantly blunted by nicotin

278 SFN-induced proteasome activity was significantly enhanced in Hsp27-

279 d to the proteasome pathway was altered, and proteasome activity was significantly reduced, compared

280 Diaphragm 20S proteasome activity was slightly increased in both venti

281 The results indicate that proteasome activity was up-regulated by low levels of co

282 gulatory beta5 subunit (PSMB5, indicative of proteasome activity) was reduced, whereas that for autop

283 ilaments in midbrain of KO mice, whereas 20S proteasome activities were decreased, which could potent

284 Three novel mechanisms for the regulation of proteasome activities were discovered in the development

285 Decreased proteasome activities were due to reduced protein levels

286 The major finding was that 20S and 26S proteasome activities were significantly elevated (1.5-

287 At 24 hours of reperfusion, myocardial proteasome activities were significantly lower whereas t

288 The FSR and proteasome activity were not different after the glutami

289 protein (XIAP), activation of NF-kappaB, and proteasome activity were required for control of cell sh

290 and 19S proteasome subunit abundance and 20S proteasome activity, were significantly decreased by CR.

291 sion, increased Zif268 expression suppressed proteasome activity, whereas Zif268 knock-out mice exhib

292 ally active Bax in platelets with attenuated proteasome activity, which was consistent with pro-apopt

293 decrease in glutamate uptake and increase in proteasome activity, which were blocked by the selective

294 ion of alpha B crystallin and stimulation of proteasome activity, which, in part, mediates the protec

295 uppressed by inhibitors of heme synthesis or proteasome activity, while SA(841)PA is sufficient to st

296 both 19S proteasome-associated DUBs and 20S proteasome activity with a mechanism distinct from that

297 Enhancing the proteasome activity with a novel proteasome activator re

298 -2-methylbutan-1-ol (AAL(S) ), or inhibiting proteasome activity with bortezomib (BORT), could suppre

299 y monocyte-derived macrophages, thus linking proteasome activity with platelet survival.

300 Furthermore, nutcracker mutants disrupt proteasome activity without affecting their distribution